TRANSMEDICS GROUP INC (1TMDX.MI) Stock Price & Overview

BIT:1TMDX • US89377M1099

Current stock price

87.2 EUR
-26.5 (-23.31%)
Last:

The current stock price of 1TMDX.MI is 87.2 EUR. Today 1TMDX.MI is down by -23.31%.

1TMDX.MI Key Statistics

Market Cap
2.991B
P/E
36.33
Fwd P/E
41.14
EPS (TTM)
2.40
Dividend Yield
N/A

1TMDX.MI Stock Performance

Today
-23.31%
1 Week
N/A
1 Month
N/A
3 Months
N/A
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

1TMDX.MI Stock Chart

TRANSMEDICS GROUP INC / 1TMDX Daily stock chart

1TMDX.MI Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to 1TMDX.MI.


Chartmill TA Rating
Chartmill Setup Rating

1TMDX.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to 1TMDX.MI. 1TMDX.MI has only an average score on both its financial health and profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

1TMDX.MI Earnings

On February 24, 2026 1TMDX.MI reported an EPS of 0.53 and a revenue of 160.76M. The company beat EPS expectations (32.92% surprise) and beat revenue expectations (1.22% surprise).

Next Earnings DateMay 5, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported$0.53
Revenue Reported160.764M
EPS Surprise 32.92%
Revenue Surprise 1.22%

1TMDX.MI Forecast & Estimates

20 analysts have analysed 1TMDX.MI and the average price target is 141.32 EUR. This implies a price increase of 62.06% is expected in the next year compared to the current price of 87.2.

For the next year, analysts expect an EPS growth of -11.67% and a revenue growth 23.07% for 1TMDX.MI


Analysts
Analysts83
Price Target141.32 (62.06%)
EPS Next Y-11.67%
Revenue Next Year23.07%

1TMDX.MI Groups

Sector & Classification

Index Membership

1TMDX.MI Financial Highlights

Over the last trailing twelve months 1TMDX.MI reported a non-GAAP Earnings per Share(EPS) of 2.4. The EPS increased by 178.22% compared to the year before.


Income Statements
Revenue(TTM)605.49M
Net Income(TTM)190.29M
Industry RankSector Rank
PM (TTM) 31.43%
ROA 17.81%
ROE 40.22%
Debt/Equity 1.06
Chartmill High Growth Momentum
EPS Q2Q%178.95%
Sales Q2Q%32.18%
EPS 1Y (TTM)178.22%
Revenue 1Y (TTM)37.13%

1TMDX.MI Ownership

Ownership
Inst Owners111.22%
Shares34.30M
Float33.28M
Ins Owners2.98%
Short Float %N/A
Short RatioN/A

About 1TMDX.MI

Company Profile

1TMDX logo image TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 898 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.

Company Info

IPO: 2019-05-02

TRANSMEDICS GROUP INC

200 Minuteman Road

Andover MASSACHUSETTS US

Employees: 898

1TMDX Company Website

1TMDX Investor Relations

Phone: 19785520900

TRANSMEDICS GROUP INC / 1TMDX.MI FAQ

Can you describe the business of TRANSMEDICS GROUP INC?

TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 898 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.


Can you provide the latest stock price for TRANSMEDICS GROUP INC?

The current stock price of 1TMDX.MI is 87.2 EUR. The price decreased by -23.31% in the last trading session.


Does 1TMDX stock pay dividends?

1TMDX.MI does not pay a dividend.


How is the ChartMill rating for TRANSMEDICS GROUP INC?

1TMDX.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.


Would investing in TRANSMEDICS GROUP INC be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1TMDX.MI.


What is TRANSMEDICS GROUP INC worth?

TRANSMEDICS GROUP INC (1TMDX.MI) has a market capitalization of 2.99B EUR. This makes 1TMDX.MI a Mid Cap stock.


Can you provide the upcoming earnings date for TRANSMEDICS GROUP INC?

TRANSMEDICS GROUP INC (1TMDX.MI) will report earnings on 2026-05-05.